US Bio association expresses negative response on biosimilars

Published: 2009-07-14 07:00:00
Updated: 2009-07-14 07:00:00
The US Senate introduced a bipartisan bill on March 26, 2009, which establishes a regulatory pathway for approval of biosimilars.

A key provision in the Senate bill is to establish five years of market exclusivity for a biologic product from the time the brand-name drug was approved. The bill ...

Fees

- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.



Most Read News


TOP
BACK
Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.